Patents by Inventor Joseph P. Lyssikatos

Joseph P. Lyssikatos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, Compositions and Methods
    Publication number: 20200317691
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 8, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20200297875
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
    Patent number: 10780073
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: September 22, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Joseph P. Lyssikatos, Julie Marie Hicks, Fredrik P. Marmsater, Qian Zhao
  • Biaryl inhibitors of Bruton'S tyrosine kinase
    Patent number: 10759783
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 1, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
    Publication number: 20200239459
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: August 7, 2019
    Publication date: July 30, 2020
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
    Patent number: 10709692
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 14, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Deuterated compounds and uses thereof
    Patent number: 10675367
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: June 9, 2020
    Assignee: Genentech Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • Compounds, compositions and methods
    Patent number: 10604535
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: March 31, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions, and methods
    Patent number: 10590114
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: March 17, 2020
    Assignee: Denali Therapautics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20200048197
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20200002345
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: September 5, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
  • BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20190218204
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 18, 2019
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20190201561
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Application
    Filed: July 31, 2018
    Publication date: July 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20190112318
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: September 13, 2018
    Publication date: April 18, 2019
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20190084975
    Abstract: The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
    Type: Application
    Filed: March 10, 2017
    Publication date: March 21, 2019
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Inhibiting agents for bruton's tyrosine kinase
    Patent number: 10227341
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: March 12, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos
  • Inhibiting agents for Bruton's tyrosine kinase
    Patent number: 10189829
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 29, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
    Publication number: 20180362522
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1)
    Publication number: 20180353480
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180334441
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.
    Type: Application
    Filed: June 14, 2018
    Publication date: November 22, 2018
    Applicant: Array Biopharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen Laird, John Robinson, Shelley Allen